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Overview 
This report presents the activities implemented by the EMCDDA and Europol in 2011 in support of 
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances (hereinafter referred to as the Decision) (1).  
 
In 2011, 49 new psychoactive substances were officially notified for the first time in the European 
Union through the information exchange mechanism, the Early-warning system (EWS), which was 
set up by the Decision. This represents the largest number of substances ever reported in a single 
year, considerably up from 2010 (41 substances) and 2009 (24 substances). Thus the number of 
substances identified in the period 2009–11 accounts for more than two thirds of the total number 
of substances notified under the terms of the Council Decision since 2005.  
 
As in 2010, the list of newly notified substances was dominated by synthetic cannabinoids (2) (23) 
and synthetic cathinones (8); these two chemical families represented about two thirds of the total 
number of substances reported in 2011 (see Annex 1 and Annex 3). The list also included five 
phenethylamines and a large number of diverse compounds belonging to an expanding range of 
chemical families that are relatively new or for which a small number of representatives had been 
previously reported — two aminoalkylbenzofurans, a thiophene derivative of methamphetamine, an 
aminoindane, and a substituted piperidine. The report also highlights the emergence of seven 
substances that are medicines, metabolites or precursors of medicines or that could be described 
as ‘designer medicines’. 
 
A brief follow-up on the increasingly diverse family of synthetic cannabinoids and on mephedrone 
— the synthetic cathinone risk assessed and subsequently controlled in 2010 — is also included in 
the report.  
 
In 2011, ‘legal highs’ (see definition in Annex 2) continued to receive high priority and political 
interest as evidenced by several initiatives at national level on awareness raising, new legislative 
formulations, as well as inclusion of new psychoactive substances in general population surveys. 
In 2011, representative studies were conducted for the first time on the prevalence of ‘legal highs’ 
and new psychoactive substances. The results indicate that prevalence levels are not substantial 
but there is a potential for rapid rise of use in certain sub-populations. Furthermore, new drugs 
appear to be widely accessible and some substances emerge both on the ‘legal highs’ and illicit 
markets. Furthermore, the online availability of ‘legal highs’ as revealed by the EMCDDA Internet 
snapshots conducted in 2011–12 has continued to increase. 
 
Finally, the conclusions of the assessment of the Council Decision 2005/387/JHA carried out by 
the European Commission (3,4) in the framework of the EU drugs action plan for 2009–12 (5) are 
also highlighted.  
                                               
(1) OJ L 127, 20.5.2005, p. 32.  
(2)  A more precise term for these compounds is ‘synthetic cannabinoid receptor agonists’, however, the term ‘synthetic 
cannabinoids’ has been widely accepted and is therefore used throughout the report. 
(3) European Commission (2011), ‘Report from the Commission on the assessment of the functioning of Council Decision 
2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances’, Brussels, 
11.7.2011, COM(2011) 430 final. 
(4) European Commission (2011), Commission staff working paper on the assessment of the functioning of Council Decision 
2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, Brussels, 
11.7.2011, SEC(2011) 912 final. 
(5) EU drugs action plan for 2009–12 (2008/C 326/09) [Official Journal of the European Union C 326/7 IV, 20.12.2008]. 
4 
1. Introduction and background 
The Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances establishes a mechanism for the rapid 
exchange of information on new psychoactive substances that may pose public health and social 
threats, including the involvement of organised crime. This allows European Union institutions and 
Member States to act on all new narcotic and psychotropic substances that appear on the 
European Union drug scene (see definitions in Annex 2). The Decision also provides for an 
assessment of the risks associated with these new substances, so that measures applicable in the 
Member States for the control of narcotic and psychotropic substances can also be applied to new 
psychoactive substances (6).  
 
The EMCDDA and Europol, in close collaboration with their networks, the Reitox National Focal 
Points (NFPs) and Europol National Units (ENUs) respectively — are assigned a central role in 
detecting and reporting new psychoactive substances (Article 4 of the Decision). Furthermore, in 
cooperation with the European Medicines Agency (EMA), the two organisations may collect, 
analyse and present information on a new psychoactive substance in the form of a joint report 
(Article 5). The joint report provides evidence-based advice to the Council and the Commission on 
the need to request a risk assessment on a new psychoactive substance. Such a risk assessment 
examines the health and social risks posed by the use of, manufacture of, and traffic in a new 
psychoactive substance, the involvement of organised crime and the possible consequences of 
control measures. In order to carry out the risk assessment, the EMCDDA convenes a special 
meeting under the auspices of its Scientific Committee (Article 6). 
 
To ensure transparency in the implementation of the Decision, Article 10 stipulates that: ‘The 
EMCDDA and Europol shall report annually to the European Parliament, the Council and the 
Commission on the implementation of this Decision. The report will take into account all aspects 
required for an assessment of the efficacy and achievements of the system created by this 
Decision. The report shall, in particular, include experience relating to coordination between the 
system set out in this Decision and the Pharmacovigilance system.’ 
 
In compliance with the above provision, the EMCDDA and Europol herewith present the seventh 
Annual Report on the implementation of the Decision for the period January to December 2011. 
The report outlines the results of the implementation, describes key issues arising from 
accumulated experiences and also serves as a monitoring tool.  
 
The report is written as a stand-alone document with its annexes kept to a minimum. The report 
frequently refers to articles of the Decision; therefore, to facilitate its reading, the full text of the 
Decision is appended (Appendix 1). When describing the notified new psychoactive substances, 
the report presents sufficiently detailed information, while avoiding highly technical descriptions 
(the complete list of newly notified psychoactive substances, which includes detailed information 
on the chemical names, the reporting Member State and date of notification is presented in Annex 
1). More comprehensive information on the new substances described in the report is available 
from the EMCDDA and Europol. Furthermore, definitions on new drugs used throughout the report 
are presented in Annex 2, and an overview of the main groups of new psychoactive substances 
monitored by the EWS is provided in Annex 3.  
 
 
                                               
(6) In compliance with the provisions of the 1961 UN Single Convention on Narcotic Drugs and the 1971 UN Convention on 
Psychotropic Substances. 
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2. Implementation arrangements and cooperation with the EU Pharmacovigilance system 
2.1 Specific implementation arrangements 
2.1.1 Assistance to national EWSs  
The EWS is frequently consulted by the Member States, individual experts, scientists and, 
increasingly, the media in relation to various new psychoactive substances. The EMCDDA 
regularly provides support to partners from the national EWSs assisting them in the identification of 
new substances. This is done by providing analytical data, exchanging data between forensic 
laboratories, cross-checking information from national databases and facilitating the exchange of 
drug samples where this is possible. Such activities prove to be useful for the identification of new 
psychoactive substances in the absence of reference materials, or where limited resources are 
available at national level.  
 
In 2011, the quality of chemical analytical data exchanged on new psychoactive substances has 
continued to improve. In addition to the data in picture format (.jpg, .pdf) already collected, gas 
chromatography coupled with mass spectrometry (GC/MS) data in zipped Chemstation format and 
nuclear magnetic resonance (NMR) data, etc., have also been regularly provided. This facilitates 
considerably the work of forensic scientists by allowing them to import directly raw data into their 
GC/MS libraries and promotes the use of more selective detection methods.  
 
Currently, the EMCDDA is finalising a compendium describing all EU national Early-warning 
systems, which will present a comprehensive overview of these systems, promote best practices 
and enhance the exchange of experiences.  
 
In the context of the project for Pre-Accession Assistance (IPA) beneficiaries (7), the EMCDDA 
facilitates the establishment of a drug information system at national level compatible with 
EMCDDA standards. In 2011, a Reitox Academy on new psychoactive substances and the early–
warning system was organised in Tirana with the participation of Europol. The main objective was 
to provide the knowledge and skills necessary to participate in the EWS network and to provide a 
basis to establish and/or strengthen the respective national systems. 
2.1.2 Annual meeting of the Reitox EWS network and First international multidisciplinary forum 
on new drugs 
In 2011, the 11th Annual meeting of the Reitox Early-warning system network was organised in 
Lisbon, followed by the First international multidisciplinary forum on new drugs (8).The purpose of 
the forum was to take stock of the state-of-the-art in the area of new drugs, anticipate future 
challenges and identify common anchor points that can inform future actions. Discussions charted 
how the new drugs phenomenon has developed over the last ten years, and explored through case 
studies differing national approaches.  
 
Participants included representatives from more than 40 countries (the 30 EMCDDA member 
countries plus Australia, Belarus, Canada, Hong Kong SAR, Israel, Japan, New Zealand, Russia, 
Switzerland, Ukraine and the United States). Furthermore, major international organisations such 
as the Inter-American Drug Abuse Control Commission (CICAD), the Pompidou Group of the 
Council of Europe, the United Nations Office on Drugs and Crime (UNODC) and the World Health 
Organization (WHO) as well as the European Commission, Europol and the European Medicines 
Agency also participated. The contributing experts came from various disciplines and included 
epidemiologists, forensic scientists, clinicians, law-enforcement officials, as well as technical staff 
from EU and international institutions selected for their technical expertise and research in the field 
of new psychoactive substances. 
                                               
(7) Participating countries: Bosnia and Herzegovina, Serbia, Montenegro, the Former Yugoslav Republic of Macedonia, Kosovo 
(under UNSCR 1244/99), Turkey and Croatia.  
(8)  Meeting documents available at: http://www.emcdda.europa.eu/events/2011/new-drugs-forum 
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A general conclusion from the forum was that there had been a paradigm shift in the drugs field, 
reflecting broader social processes. The speed at which the new drug phenomenon develops calls 
for a re-evaluation of the information sources used and the ways in which we disseminate 
information to inform policy, practice and the general public. Furthermore, the forum highlighted the 
need to better understand the possible acute and chronic health implications of the use of these 
new substances and to identify and monitor patterns and trends in their use. A starting point would 
be: to map out the future research agenda, particularly focusing on developing common concepts, 
terminology and instruments; to invest in forensic science research and the detection of new 
substances available on the market; to take a more holistic analysis to understand better the 
interplay between established illicit drugs and new psychoactive substances; and to develop 
theoretical models that could help predict the substances that may pose particular risks or have the 
potential to become established. (9) 
 
In view of the importance of international cooperation in this area and the high interest from all 
international partners, the US National Institute on Drug Abuse (NIDA) decided to partner with the 
EMCDDA in co-organising the Second interdisciplinary forum on new and emerging psychoactive 
substances in 2012 (10). 
2.1.3 Structured monitoring of the Internet — online availability of ‘legal highs’  
To complement the main EWS data sources such as seizures and reports on use and toxicity, the 
EMCDDA actively monitors the online availability of unregulated psychoactive substances and 
products. One of the main potentials for the EMCDDA to be of added value in this area lies in the 
multilingual approach and the utilisation of sound methodology over time (11).  
EMCDDA Internet monitoring is carried out in the form of snapshots, which are performed during a 
short time window on one or more substances and/or products. In 2011, two multilingual, wide-
scope EMCDDA snapshots were carried out on the same substances as the 2010 annual 
snapshot. Furthermore, at the beginning of 2012 a snapshot was conducted in 20 EU languages 
plus Ukrainian, Russian and Norwegian. 
The total number of online drugs shops offering at least one psychoactive substance/product rose 
from 170 in January 2010 to 314 in January 2011. The increase continued with 630 shops 
identified in July 2011 and 690 in January 2012. In general, these sites more often sell new drugs 
under names such as ‘herbal highs’ or ‘research chemicals’ than under the term ‘legal highs’. The 
main increase seems to be due to a rise in the number of ‘US shops’ although establishing the 
country of origin of online shops is difficult. In 2011, mephedrone continued to be available on the 
Internet through online shops although at fewer sites and at higher prices. 
Some Member States carry out additional Internet snapshots in their own languages. For example, 
in January and February 2011 the Hungarian NFP carried out an Internet snapshot on the online 
sale of MDPV, JWH-018, GBL and mefildronon (a fictitious compound), identifying 19 online shops 
offering at least one of the four substances. In Italy, France, Slovakia and Romania the online 
sales are also monitored.  
Test purchasing of new psychoactive substances and forensic studies have shown that the 
contents of products are variable — they may contain controlled substances, the composition may 
vary from sample to sample, and a psychoactive substance can be sold under different product 
names. In this context, the EMCDDA has launched a specific project — ‘Match’ — that attempts to 
relate products’ names to their content. The data integrated in this searchable tool include 
                                               
(9) EMCDDA (2011), ‘Concluding remarks of the First international multidisciplinary forum on new drugs’. Available at: 
http://www.emcdda.europa.eu/news/2011/new-drugs-forum-conclusion  
(10) 2012 NIDA International Forum, New and emerging psychoactive substances: second interdisciplinary forum, June 8–11, 
2012, Palm Springs, California, USA. Information available at: http://www.cvent.com/events/2012-nida-international-
forum/event-summary-993dab44351348b1874d61aba460c8e5.aspx  
(11) EMCDDA briefing paper (2011), ‘Online sales of new psychoactive substances/‘legal highs’: summary of results from the 
2011 multilingual snapshots’ at: http://www.emcdda.europa.eu/publications/scientific-studies/2011/snapshot  
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information from Reporting Forms, national test purchases, scientific literature, and Internet 
snapshots. By end of 2011, the ‘Match’ tool comprised more than 300 product/substance(s) entries 
thereby providing an insight into the most commonly sold products/substances. This project, 
however, needs to be further conceptualised and automatised. 
2.2 Cooperation with the EMA and the Pharmacovigilance system 
 
The European Medicines Agency (EMA) is a key partner in the implementation of the system set 
up by the Decision. The EMCDDA and EMA have established a mechanism for bilateral exchange 
of information on the basis of data available through the Early-warning system and the European 
Union Pharmacovigilance system. Electronic tools such as the existing databases — 
EudraVigilance, EMA and the European Database on New Drugs (EDND), EMCDDA — are being 
used to enable a rapid and reliable exchange of information. The regular information exchange 
between the EMCDDA and EMA includes formal reports on new psychoactive substances through 
Reporting Forms, as well as ad hoc reports on misused medicines in order to complement the 
reporting via the EU Pharmacovigilance system.  
 
The EMA is currently preparing a Good vigilances practice (GVP) guide to formalise and cover the 
provisions of Regulation (EU) 1235/2010 (12). Pursuant to Article 28c of the Regulation, in 2011 a 
draft implementation proposal was prepared by the EMA and the EMCDDA. The draft proposal 
foresees that EMA EudraVigilance queries will provide to the EMCDDA, on request, data on 
relevant preferred terms (PTs) from the standardised MedDRA (13) queries (SMQs) ‘drug abuse, 
dependence and withdrawal’.  
 
In 2011, consultations and exchange of information between EMCDDA and EMA took place on two 
substances:  
 
− 5-HTP or oxitriptan (INN) — a widely marketed off-the-shelf food (dietary) supplement, 
which can be used as a precursor to 5-hydroxytryptamine. The EMA reported 32 specific 
adverse reactions, which were extracted from EudraVigilance.  
 
− phenazepam — an internationally non-controlled benzodiazepine used for the treatment of 
epilepsy, alcohol withdrawal syndrome, insomnia and anxiety in Russia and some 
neighbouring countries. Two cases related to phenazepam were found in EudraVigilance: 
one of them reporting hallucination (PT), and the other one reporting respiratory 
depression, asthma, headache and toxicity to various agents. 
 
 
                                               
(12)  Article 28c, of Regulation (EU) 1235/2010 stipulates that the EMA and the EMCDDA ‘shall exchange information that they 
receive on the abuse of medicinal products including information related to illicit drugs’. The Regulation will apply as of 2 July 
2012.  
(13) Medical Dictionary for Regulatory Activities.  
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3. Results achieved in 2011  
3.1 New psychoactive substances notified in 2011 
 
During 2011, a total of 49 new psychoactive substances were officially notified for the first time in 
the European Union via the EWS (see Annex 1 and Graph 1). This is the largest number of 
substances ever reported in a single year. The marked increase in the number of substances 
notified takes place in the context of a continuous development of the ‘legal highs’ phenomenon 
and probably reflects both the number of substances available in the EU as well as the improved 
reporting capacities of national Early-warning systems due to increased awareness about new 
drugs among various professionals and high interest at national level. Some of the newly identified 
substances have been actively sought through test purchases of ‘legal highs’ products on the 
Internet and from specialised shops (see Graph 2). 
 
Graph 1. Number of new psychoactive substances notified in 2005–11, by year 
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Graph 2. Source of new psychoactive substances notified in 2011, by type of notification  
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Of the newly identified substances, synthetic cannabinoids and cathinones represented about two 
thirds of the number of substances notified in 2011 (but also of the total number of substances 
reported under the terms of the Council Decision), thus becoming two of the largest drug families 
monitored by the EWS. The 23 new synthetic cannabinoid receptor agonists reported (14) belonged 
to different sub-families (see 3.3 below). Furthermore, eight new synthetic cathinones (15) and five 
substances belonging to the phenethylamine chemical family (16) were reported.  
 
There were also compounds belonging to an expanding range of chemical families that are 
relatively new or for which a small number of representatives had been previously reported — 2 
aminoalkylbenzofurans (cp. Annex 1, substances 22 and 23), a thiophene analogue of 
methamphetamine (cp. Annex 1, substance 3), and aminoindane (cp. Annex 1, substance 9), and 
a substituted piperidine (cp. Annex 1, substance 37). Also included are seven substances, which 
are medicines, metabolites or precursors of medicines or that could be described as ‘designer 
medicines’ (17). 
 
From the above list, it is worth noting the appearance of several derivatives of controlled drugs:  
 
− two aminopropylbenzofuran (APB) positional isomers — unsaturated benzofuran 
derivatives of APDB compounds and deoxygenated derivatives of the controlled drug 
methylenedioxiamphetamine (MDA) — which act as serotonin (5-HT(2c)) agonists;  
 
− methylthienylpropamine, a thiophene analogue of methamphetamine;  
 
− 4-MeO-PCP, a derivative of phencyclidine (PCP);  
 
− methoxyphenamine, a positional isomer of para-methoxymethamphetamine (PMMA);  
 
− and 4-benzylpiperidine, a substituted piperidine structurally very close to benzylpiperazine 
(BZP). 
 
The aminoindane 5-iodo-2-aminoindane (5-IAI) already anticipated in 2010 by an Internet 
snapshot) was also identified in 2011. 
 
The list of substances with medicinal properties or ‘designer medicines’ (substances designed to 
mimic the effects of known medicines by slightly altering their chemical structure) included 
derivatives and metabolites of several medicines:  
 
− Phenazepam and etizolam, two benzodiazepines used in some countries. Phenazepam is 
scheduled in Finland and Norway, furthermore, in 2011, the Advisory Council on the Misuse 
of Drugs published advice to Government in relation to phenazepam, recommending that 
the substance be brought under the control in the UK;  
 
− Ethylphenidate, a derivative and metabolite of methylphenidate (Ritalin), a CNS stimulant 
used in the treatment of attention deficit hyperactivity disorder (ADHD); 
 
− Camfetamine, a derivative of fencamfamine (Reactivan) used for the treatment of 
depressive daytime fatigue, lack of concentration and lethargy, in individuals with chronic 
medical conditions; 
 
− 5-hydroxytryptophan (Oxitriptan), a chemical precursor as well as metabolic intermediate in 
the biosynthesis of the neurotransmitters serotonin and melatonin from tryptophan; 
                                               
(14)  Annex 1, substances 1, 4, 6–8, 10, 13–16, 18, 21, 24, 26–32, 43, 45 and 48. 
(15)  Annex 1, substances 12, 33–36, 38, 39 and 47. 
(16)  Annex 1, substances 5, 11, 19, 40 and 49. 
(17)  Annex 1, substances 2, 17, 20 25, 41, 42, 44 and 46. 
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− 3-amino-1-phenyl-butane, a metabolite and a precursor of Labetalol, an alpha/beta 
adrenergic antagonist used to treat high blood pressure and angina pectoris; and  
 
− Ostarine, a tissue-selective androgen receptor modulator (SARM) under development for 
the prevention and treatment of muscle wasting in patients with cell lung cancer (see 
section 4.4).  
 
Following the formal notifications, new substance profiles were created in the European Database 
on New Drugs (EDND). In addition, the EMCDDA implements longer-term monitoring through 
biannual EWS reports. Based on the information collected and analysed, the list of all notified 
substances is reviewed regularly by the EMCDDA and Europol in order to identify those with a 
potential to trigger a joint report. At the time of writing this report, no substance merited the 
production of a joint report. However, the EWS remains vigilant as there are a few substances of 
concern that need to be proactively followed up on (see subsection 3.4.1). 
3.2 Synthetic cannabinoids and follow-up on mephedrone  
3.2.1  Synthetic cannabinoids 
In 2011, 23 new synthetic cannabinoid receptor agonists were reported via the EWS, bringing the 
total number of synthetic cannabinoids reported to 45, the largest drug family monitored by the 
EMCDDA.  
 
The synthetic cannabinoid compounds reported between 2008 and 2010 belonged to five different 
chemical groups — naphthoylindoles, cyclohexylphenols, tricyclic terpenoids, phenylacetylindoles 
and benzoylindoles. In addition, five new groups emerged during 2011 and early 2012 — 
naphthoylpyrroles, naphthoylnaphthalenes, adamantoylindoles (2011), and quinones and 
cyclopropylindoles (reported in 2012). Furthermore, allosteric modulators, a new type of agonists 
that belong to chemically diverse families, were identified for the first time. Allosteric modulators 
bind to receptor sites that are topographically distinct from the agonist-binding site and cause a 
conformational change in the receptor that alters the activity of the ligand.  
 
While in the previous reporting period control measures mainly consisted of individual listing of 
already identified synthetic cannabinoids, in 2011 several countries adopted ‘generic’ or ‘generic-
like’ definitions similar to the ones devised by the UK (2009) and Ireland (2010) (18). Most of the 
generic controls applied currently cover five of the most ‘common’ families — naphthoylindoles, 
naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles and hydroxycyclohexylphenols. 
Although there are some exceptions, for instance, the Italian legislation is one of the few that 
covers the family of benzoylindoles (to which RCS-4 or AM-694 belong).  
 
Following the first adverse effects related to synthetic cannabinoids JWH-122 reported in 2010 in 
Italy and Germany, several studies have described toxicity following the use of ‘Spice’-like 
products. In 2011, a German study reported intoxications following recreational use of herbal 
products containing synthetic cannabinoids (19). The case series consisted of 29 cases hospitalised 
after inhalation of herbal mixtures containing synthetic cannabinoids. Most of the intoxications were 
due to JWH-210 (12 cases), JWH-122 (11), JWH-081 (7) and JWH-250 (4). The most frequent 
symptoms were: tachycardia (76% of the patients), agitation (41%), change of 
perception/hallucination (38%), hypertension (34%), elevation of plasma glucose (31%), decrease 
in plasma potassium concentration (28%) and nausea/vomiting (28%). 
 
                                               
(18) Austria, Italy and Lithuania. 
(19) Szabo, B., Auwaerter, V., Kneisel, S. and Hermanns-Clausen, M. (2011), ‘Intoxications following recreational use of herbal 
products containing synthetic cannabinoids’, IACM 6th Conference on Cannabinoids in Medicine and 5th European Workshop 
on Cannabinoid Research, 8-10 September 2011. 
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The extent to which these products are used is largely unknown. A number of surveys aimed at 
examining the prevalence of use of ‘Spice’-like products have been launched but the coverage and 
representativeness of the studies carried out are still limited (see section 4.1). 
3.2.2  Mephedrone 
The Report on the risk assessment of mephedrone in the framework of the Council Decision on 
new psychoactive substances was published in the EMCDDA risk assessment series in May 2011 
(20). One year after the Decision to control mephedrone (21), 26 Member States, Norway and 
Croatia control the substance under drug legislation (22).  
 
Mephedrone is not commonly included in general population surveys, however a few recent 
studies have assessed the prevalence of its use after the ban (see section 4.1). For example, 
results from the British Crime Survey 2010/11 (23), carried out among a nationally representative 
population of 16- to 59-year-olds in England and Wales, showed that last year mephedrone use 
(1.4%) was at a similar level to ecstasy use, i.e. the third most used drug within this age group. In 
the population aged 16–24 mephedrone was as popular as powder cocaine (4.4%), the second 
most used drug among young people. Of those who used mephedrone in the last year, the majority 
had also taken another drug (mainly cannabis, cocaine or ecstasy). Therefore, it is likely that it is 
existing users of drugs taking mephedrone rather than new users drawn to drug taking. An 
important caveat to understand the significance of these figures is that the data collection for the 
survey covered pre-and post-mephedrone ban periods.  
 
In 2010–11, the Hungarian NFP/EWS reported increasing prevalence of the injecting use of 
mephedrone and other cathinones. 
3.3 Public health warnings  
 
The Council Decision stimulates the identification, monitoring and exchange of information on 
emerging trends in new uses of existing substances and on possible public health-related 
measures. The warning on adverse health effects of new psychoactive substances through timely 
and rapid public health alerts is one of the core activities of the EMCDDA EWS. In addition, in 
2011, the EWS issued public health warnings to the Reitox network concerning unusual hazards of 
occurrences related to controlled drugs.  
3.4.1  Adverse health effects related to new psychoactive substances 
In 2011, the EWS issued public health warnings concerning adverse health effects related to the 
following substances: 
 
– Para-methoxymethylamphetamine (PMMA) 
PMMA was risk assessed in 2001 in the framework of the 1997 Joint Action on new synthetic 
drugs (24) and consequently controlled at European level. It is known to have considerable toxicity 
and to have been responsible for fatal overdoses in the past. As a follow-up to the warnings sent 
by the EWS in 2010 on the PMMA-related deaths and seizures in Norway, the Norwegian Institute 
of Public Health informed that there had been a total of 20 PMMA-related deaths between July 
2010 and September 2011. Alerts on fatal cases related to the substance were also received by 
the Austrian NFP and the UK NFP/EWS (from the Scottish Crime and Drug Enforcement Agency).  
 
                                               
(20) EMCDDA (2011), Report on the risk assessment of mephedrone in the framework of the Council Decision on new 
psychoactive substances. Also available at: http://www.emcdda.europa.eu/html.cfm/index116639EN.html  
(21) Council Decision 2010/759/EU of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures. 
OJ L 322, 8.12.2010, p. 44. 
(22) Except Netherlands (planned for March 2012) and Turkey. 
(23) Smith, K., Flatley, J. (2011), ‘Drug misuse declared: findings from the 2010/11 British Crime Survey England and Wales’, July 
2011, UK Home Office Statistical Bulletin.  
(24)  EMCDDA (2003), Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs. Also 
available at: http://www.emcdda.europa.eu/html.cfm/index33349EN.html 
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An important new development related to PMMA was discovery of the substance in ‘legal high’ 
products in Scotland and in Spain. The appearance of a controlled substance in ‘legal high’ 
products may suggest an interplay between the ‘legal high’ and illicit markets, and clearly poses a 
threat to users.  
 
– 4-Methylamphetamine 
This phenethylamine closely related to amphetamine was researched in the past as an appetite 
suppressant and has serotonin, norepinephrine, and dopamine releasing properties. In October 
2011, the Belgian EWS (Reitox NFP) reported that three fatalities and three intoxications related to 
the substance occurred in August/September 2011. In most of the cases, amphetamine was also 
identified in blood and/or collected samples. Following this alert, the UK NFP/EWS (ROAR 
Forensics) informed on two previous fatalities (2010 and 2011) involving the same substance.  
 
Following this alert, the EMCDDA requested Europol to appraise the information available on this 
substance through the 27 Europol National Units (ENUs). Thirteen ENUs answered the request, 
with Austria, Finland and Luxembourg reporting new information on seizures. 
 
– 3,4-methylenedioxypyrovalerone (MDPV) 
Following the reports on adverse effects and fatalities received in 2010 by Finland, in 2011 the 
Finnish Poison Control Center reported several enquiries concerning this cathinone. The most 
typical clinical symptoms were agitation, tachycardia, hypertension and dyspnea, and less 
commonly, a decreased level of consciousness and convulsions. The Belgian and the Greek EWS 
also informed on psychotic episodes associated with MDPV.  
 
– Pipradol-related substances, diphenylprolinol (D2PM)  
Following the alerts issued in 2010 on desoxypipradol (2-DPMP) and 2-(diphenylmethyl)pyrrolidine 
(desoxy-D2PM), a study on five analytically confirmed cases of acute toxicity related to the 
recreational use of D2PM was reported in the UK. Patients presented with ongoing prolonged 
neuropsychiatric symptoms of agitation, anxiety and insomnia. None had evidence of 
sympathomimetic toxicity on presentation to the emergency department. Following these alerts, the 
Advisory Council on the Misuse of Drugs published advice to the UK Government in relation to 
diphenylprolinol (D2PM) and diphenylmethylpyrrolidine and desoxypipradrol recommending that 
the substances be brought under control. 
 
– Methoxetamine 
This arylcyclohexylamine — a derivative of ketamine and phencyclidine — was reported for the 
first time in November 2010 by the UK NFP. Its mechanism of action involves NMDA receptor 
blockade and dopamine reuptake inhibition. A study reporting the acute toxicity associated with the 
recreational use of methoxetamine in a case series of three patients was reported in the UK (25). 
Clinical features were suggestive of a dissociative (catatonic) state similar to that seen with 
ketamine; in addition, the patients had clinical features of acute sympathomimetic toxicity with 
significant tachycardia and hypertension. In 2012, upon a request from the UK the EMCDDA 
launched an information request on this substance. 
 
– Unusual mixture of drugs 
Adverse effects related to an unusual mixture of drugs involving 3- or 4-MeO-PCP, 2C-E and 
possibly N,N-dimethylcathinone were reported in Norway, in August 2011. The National Criminal 
Investigation Service received reports of several overdoses with hospitalisation, nausea and 
muscle spasms among users of the powder. 
3.4.2  Hazards related to controlled substances 
The potent synthetic opioid fentanyl was detected in four cases in Scotland in the period March to 
April 2011. In all cases, small quantities of white powder containing fentanyl were detected while 
no opium alkaloids were identified. The substances were being marketed to heroin users as 'China 
                                               
(25) Wood, D. M., Davies, S., Puchnarewicz, M., Johnston, A. and Dargan, P. I., (2011), ‘Acute toxicity associated with the 
recreational use of the ketamine derivative methoxetamine’, Eur J Clin Pharmacol DOI 10.1007/s00228-011-1199-9. 
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White’ heroin. Fentanyl was detected in two drug-related deaths in Scotland and one in Greece, as 
well as in two intoxications in Bulgaria. 
 
In March 2011, the French health authorities alerted on six intoxications and a fatality related to the 
benzodiazepine alprazolam, used as a cutting agent in heroin. In Ireland, two deaths were 
attributed to counterfeit benzodiazepines sold as Xanax (alprazolam) purchased in the UK.  
 
In October 2011, increased media coverage in Germany of the drug called ‘crocodile’ prompted a 
collection of information and an EWS warning. 'Crocodile' is a self-made drug/preparation 
encountered in Russia, reported to contain among other substances desomorphine, an opiate 
known for a long time, which is controlled by the 1961 UN Drug Convention on narcotic substances 
(Schedules I and IV). Following the alert, the French SINTES issued an information note on the 
case. There are no forensic or toxicological data confirming the availability of ‘crocodile’ in the EU. 
 
In 2011 the EMCDDA received reports from Greece of a drug circulating in Athens, called 'SISA'. 
Analyses of seizures confirmed that the active ingredient was methamphetamine. According to 
user reports, the substance is most frequently smoked, although it can be also injected and it can 
be used in combination with heroin and/or other medicines. The reported effects are similar to 
those of methamphetamine. Further investigation is ongoing in 2012 in order to establish a more 
precise picture and potential fatalities related to this drug. 
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4. Epidemiology and new approaches 
4.1 Emerging prevalence data on new drugs  
 
Prevalence data on new psychoactive substances are scarce and when available have many 
limitations and associated methodological issues, for example lack of common definitions as well 
as small and often non-representative population samples.  
 
In Europe, there are few studies on the prevalence of ‘legal highs’, as a collective term or referring 
to individual substances. In 2010, a small number of surveys explored the extent, patterns of use 
and availability of mephedrone in Europe, primarily Internet surveys and studies with self-selected 
convenience samples. In 2011, representative studies were conducted for the first time on the 
prevalence of ‘legal highs’ and new psychoactive substances (see section 3.2.2). The results 
indicate that prevalence levels are not high but there is potential for rapid rise of use in certain sub-
populations.  
 
At European level, the 2011 Eurobarometer survey interviewed over 12 000 young people (aged 
15–24) across Europe. Overall, 5% of respondents reported having used ‘legal highs’. In most EU 
countries, not more than 1 in 20 young people reported having used legal substances that imitated 
the effects of illicit drugs. However, in the UK, Latvia and Poland, self-reported use of ‘legal highs’ 
was close to 10% and respondents in Ireland were by far the most likely to say they had used new 
substances (16%). Of the young people who had experience with new substances, 54% indicated 
that they had been offered such substances by friends, against 37% who had been offered such 
substances during a party or in a pub, and 33% who had bought these substances in a specialised 
shop, e.g. a smart shop. Just 7% of interviewees had bought these substances over the Internet. 
 
In Spain, the national survey on drug use in students aged 14 to 18 years (2010) with a sample of 
25 000, introduced a special module on emerging drugs, the prevalence of these substances and 
the perceived risk and availability. The nine substances studied were: ketamine, ‘Spice’, 
piperazines, mephedrone, nexus (2C-B), methamphetamine, magic mushrooms, ‘research 
chemicals’ and ‘legal highs’. Overall, 3.5% of students reported having consumed one or more of 
the drugs mentioned above at some time in their life, 2.5% had consumed during the previous year 
and 1.3% last month. The results showed a low level of prevalence of use of mephedrone among 
secondary school students aged 14–18 (0.4% lifetime use). The prevalence of consumption in the 
last month also showed very low levels (0.2%), confirming the sporadic nature and experimental 
use of these substances among students in this age group. Low percentages of ‘Spice’ products 
were also reported: 1.1%, 0.8% and 0.5% for lifetime, last year and last month prevalence, 
respectively. 
 
Mephedrone and ‘legal highs’ were included for the first time in the drug prevalence survey of 
households in Ireland and Northern Ireland conducted in 2010/11, i.e. after mephedrone was put 
under control. The sample comprised 7 669 respondents, aged between 15 and 64. In Northern 
Ireland, the prevalence rate was around 2%, 1% and 0.1% (lifetime, last year and last month) for 
both mephedrone and ‘legal highs’ (26). The lifetime prevalence rate for people aged 15–24 was 
6% for both mephedrone and ‘legal highs’. In the Republic of Ireland, with regard to drug use in the 
year prior to the survey, new psychoactive substances (4%) were the second most frequently 
reported illegal drugs after cannabis (6%). People aged between 15–24 years reported the highest 
last year use of any illegal drug (15%). Those aged 15–24 years also reported the highest use of 
cannabis (13%), new psychoactive substances (27) (10%), amphetamines (1.5%), ecstasy (1.1%) 
and magic mushrooms (1%). 
 
                                               
(26) In Northern Ireland, the category ‘legal highs’ includes party pills, herbal highs, party powders, Kratom and Salvia Divinorum.  
(27) In the Republic of Ireland the measurement of new psychoactive substances included herbal smoking mixtures/incense, party 
pills or herbal highs, bath salts, plant feeders or other powders, Kratom (Krypton), Salvia, Magic Mint, Divine Mint or Sally D 
and other new psychoactive substances mentioned by the respondent.  
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A 2008 Polish study among a representative national sample of about 1 250 students aged 18–19 
found that just 3.5% had used ‘legal highs’ at least once in their life, while a follow-up study in 2010 
reported an increase to 11.4%. The use of ‘legal highs’ during the last 12 months was reported by 
around 2.6% of students in 2008, and increased to 7.2% in 2010. This period saw a rapid 
development of the smart/head shops sales network in Poland, with the number of shops 
increasing from around 40 in 2008 to more than 1 500 in 2010. The survey was conducted just 
after the closure of shops. In terms of awareness and purchasing experience, the 2010 survey 
found: 90% of the respondents had heard about ‘legal highs’, 27% had visited a smart/head shop 
(40% of these made a purchase), while only 1% bought them online. As for types of purchase: 
31% bought herbal concoctions, 6% sniffing powders, and 4% paraphernalia.  
 
In contrast, an additional Polish general population study conducted in both 2009 and 2010 among 
one thousand respondents aged 15–75, revealed a divergent trend on the consumption levels of 
‘legal highs’ — in particular, a drop in use was recorded after closure of the Polish smart shop 
network. In 2010, 3% of the respondents admitted using ‘legal highs’ at least once — a reduction 
from 6% in 2009. Fewer than 2% had used them in the last 12 months, compared with 5% in 2009. 
 
A 2009 study from Frankfurt, Germany, also reported use of ‘Spice’ among students (28). In 2009 
(sample of 1 157 respondents), a total of 7% of the 15- to 18-year-olds in Frankfurt reported 
experience with smoking mixtures. While there was little change in this figure in comparison to 
2008 (sample of 1 029 respondents), last month prevalence declined from 3% to 1% with repeated 
use representing an exception. Students with experience in the consumption of 'Spice' were, for 
the most part, experienced cannabis consumers. 
4.2 EMCDDA ‘Trendspotter’ methodology 
 
At the end of 2010, an alert and information appraisal on a heroin drought, reported mainly in the 
UK and Ireland, was sent to the EWS network. While in some countries there seemed to be no 
evidence of such shortage, others reported varying purity in the heroin available. In October 2011, 
as a follow-up on this phenomenon, an information request was sent out to the EWS network to 
appraise the updated information on this.  
 
The first EMCDDA Trendspotter meeting, on Recent shocks in the European heroin market: 
explanations and ramifications, took place in Lisbon on 18–19 October 2011 (29). The purpose of 
the meeting was to increase understanding of the 2010/2011 heroin shortage reported by some 
European countries, to explore issues of drug replacement, and to undertake a first pilot of 
EMCDDA ‘trendspotter’ methodology. Invited participants presented recent trends in heroin 
availability, use and replacement of heroin by other illicit drugs or medicines, providing insight from 
different disciplinary perspectives. 
 
The ‘trendspotter’ methodology involves the collection of data from multiple sources and uses a 
number of different investigative approaches. The heroin market assessment included a review of 
the available literature, an electronic survey of experts and three rounds of data collection with the 
EMCDDA network of Reitox focal points and EWS network. In addition, data were collected in one 
country using a questionnaire posted in Twitter. The input received covered multiple perspectives 
on the heroin market including supply-side and law-enforcement expertise, forensic and monitoring 
data, treatment and care experience, and drug user perspectives. Analysis involved triangulation of 
the available data with a view to providing as complete and verified a picture as possible.  
 
In summary, some European countries experienced severe heroin shortages or droughts in the 
2010 to 2011 period (30). A key conclusion from the meeting was that it is important to take a 
                                               
(28) Werse, B. (2010), ‘Spice, Smoke, Sence & Co. – herbal mixtures containing cannabinoids: use and motivation for use against 
the backdrop of changing laws’, Report from the German Federal Ministry of Health Division 125: Addiction and Drugs. 
(29)  Meeting documents available at: http://www.emcdda.europa.eu/events/2011/trendspotter 
(30)  EMCDDA (2011), ‘Summary report from EMCDDA Trendspotter meeting 18–19 October 2011’. Available at: 
http://www.emcdda.europa.eu/scientific-studies/2011/trendspotters-report 
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holistic approach to the European drug market, moving away from a focus on individual 
substances to consideration of a complex market model with a range of competing products. It 
appears that both (new) synthetic drugs and medicines may be becoming more important in 
European illicit drug markets. Supply-side action is probably a factor in recent heroin shortages. 
Both bounce-back and recovery appear to be occurring and, arguably, Europe may now have a 
faster moving and more dynamic illicit drug marketplace. 
4.3 Sewage epidemiology: wastewater analysis 
 
Sewage epidemiology or wastewater analysis is a rapidly developing scientific discipline with the 
potential for monitoring population level trends in illicit and new drug consumption. Advances in 
analytical chemistry have made it possible to identify urinary excretion of illicit or new drugs and 
their main metabolites in wastewater at very low concentrations. This is comparable to taking a 
much diluted urine sample from an entire community (rather than from an individual user). With 
certain assumptions, it is possible to back-calculate from the amount of the metabolite in the 
wastewater to an estimate of the amount of a drug consumed in a community. 
 
While early research focused on identifying cocaine and its metabolites in wastewater, recent 
studies have produced estimates on levels of cannabis, amphetamine, methamphetamine, heroin 
and methadone. The identification of less commonly used drugs, such as ketamine and new 
psychoactive substances, appears promising. Two expert meetings on wastewater analysis were 
organised by the EMCDDA in 2011 (31).  
4.4 Computer-aided prediction of properties (toxicity, psychoactivity)  
 
According to the similarity principle, molecules with similar chemical structures possess similar 
physicochemical properties and biological activities. The concept of molecular similarity has been 
exploited in drug discovery and similarity methods have been employed in the prediction of 
physicochemical properties (solubility, partitioning coefficient), estimation of absorption, 
distribution, metabolism, excretion and toxicity (ADME/Tox), etc.  
 
Computational modelling for the assessment of toxicity entails prediction of the binding and 
efficacy of molecules at biological receptors; thus some of the key properties to be examined are 
solvation effects and heterogeneity of binding sites. Chemogenomics comprises a systematic 
relationship between targets and ligands that are used as target modulators in living systems. In 
silico target prediction tools can suggest likely biological targets of small molecules via data mining 
in target-annotated chemical databases.  
 
The psychoactive potential of Ostarine (first notified in 2011, see Annex 1), an androgen receptor 
targeting agent used for oral testosterone replacement therapy, male contraception, treating and 
imaging prostate cancer was assessed by a computational study using in silico methods (32). The 
analysis was two-fold: firstly, it entailed a prediction of the protein targets likely to be modulated by 
the compound and, secondly, the likelihood of the substance to permeate the CNS was assessed. 
The results of the study indicated that no targets known to be involved in psychoactive effects 
seem to be modulated by Ostarine and that the substance is unlikely to permeate the CNS 
although possibilities of active transport could not be ruled out. Therefore, based on currently 
available data, Ostarine appears to be unlikely to cause psychomodulatory effects in human. 
 
 
                                               
(31) http://www.emcdda.europa.eu/wastewater-analysis  
(32) Mohd-Fauzi, F., Bender, A. (2012), Computational analysis of the possibility of Ostarine eliciting psychoactive effects, 
University of Cambridge. 
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5. Production and distribution of new psychoactive substances  
5.1 Europol  
 
Over the last years, most of the new psychoactive substances notified by Member States to the 
EMCDDA via the EWS were produced (synthesised) and acquired (imported) from outside Europe. 
China and, to a lesser extent, India were identified as the source countries. With the production of 
new psychoactive substances taking place predominantly outside of Europe, a new niche for 
lucrative business has emerged, as reported by Belgium, Ireland and the Netherlands. Facilities 
which involve the importation, mixing and packaging of these substances in Europe have 
developed. The products are subsequently sold mainly as ‘legal highs’ via the Internet, smart and 
head shops. The initial production of such products/substances is very cheap and can provide 
easy profits to Organised Crime Groups (OCGs) and individual entrepreneurs.  
 
Europol has received reports indicating that European Organised Crime Groups are engaged in 
both the tableting and marketing of these substances as ecstasy (MDMA) often disguised by use of 
logos usually associated with this type of drug. This has been related to the decrease in the 
availability of MDMA precursors, reported in 2010/11.  
 
At the end of 2010 and the beginning of 2011, Europol’s project Synergy was assigned an active 
role in the coordination of investigations concerning new psychoactive substances, such as the 
trafficking of mephedrone. The substance, manufactured in China, often entered European 
countries in which it was controlled, via a third country where it was not. Furthermore, Europol has 
become increasingly involved in transnational cases concerning mixing/packaging facilities and the 
trafficking of new psychoactive substances. Consequently, there has been an increase in reported 
seizures of new psychoactive substances submitted to the Synergy project’s related expert 
systems (33) — with minor seizures reported in Estonia, Hungary, Latvia and Germany and more 
significant seizures involving consignments of hundreds of kilograms entering the European Union 
via the Netherlands. 
 
In contrast to the main sources of these new psychoactive substances, Poland reported the 
dismantling of a production site in late 2011 which resulted in the seizure of 5 kg of mephedrone 
and charges related to the illicit production and trafficking of a further 50 kg. Other production 
places (points of importation, mixing and packaging) include facilities seized in Ireland, Belgium 
and the Netherlands. At the facility found in the Netherlands, 150 kg of white powders and 
approximately 20 000 packages containing several synthetic cannabinoids were seized.  
 
Information on seizures of small quantities has been received from Hungary, Germany and Estonia 
concerning mainly cathinones and synthetic cannabinoids, and from Denmark, concerning mCPP. 
More substantial seizures concerning mainly unspecified new psychoactive substances were 
reported in Latvia (about 5 kg), the Netherlands (150 kg), Czech Republic (more than 20 kg of 
mephedrone originating from India) and Spain (seizure from a head shop totalling 96 kg). 
 
5.2 The UK Serious Organised Crime Agency (SOCA) 
 
In the UK, the Serious Organised Crime Agency (SOCA) found that some seized new psychoactive 
substances, sold as ‘plant food’ or ‘research chemicals’, contained controlled drugs. This is 
particularly the case for cathinones and piperazines. A recent report of forensic analysis of seized 
samples indicated that 19% of samples tested contained a controlled substance (34) — 20%, 18% 
and 22% contained cathinones, synthetic cannabinoids and piperazines, respectively.  
 
                                               
(33)  All project Synergy subject-related expert systems are incorporated into a database system comprising the Europol Ecstasy 
Logo System, Europol Illicit Laboratory Comparison System, Europol Synthetic Drug System and Europol Synthetic Drugs 
Other Substances sub-systems. 
(34)  Serious Organised Crime Agency (2011), ‘Drugs: risks associated with new psychoactive substances’, Intelligence report. 
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The extent to which organised criminals are involved in the trade of new drugs is unclear. 
Currently, the market seems to be driven by opportunist entrepreneurs taking advantage of the 
Internet for marketing and selling their products, and consumers who believe they are purchasing 
substances which are legal and safe but which may in fact contain hazardous substances. 
  
In 2010/11 SOCA took action against websites which continued to advertise mephedrone and 
naphyrone for sale following their classification as Class B drugs in April and July 2010 
respectively. In 2010/11 over 120 websites were closed down as a result of SOCA action, 
disrupting the supply of these drugs (35). 
 
 
                                               
(35) Serious Organised Crime Agency (2011), Serious Organised Crime Agency Annual Report and Accounts 2010/11. Available 
at: http://www.soca.gov.uk/about-soca/library/doc_download/301-annual-report-2010-11.pdf 
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6. The way forward 
New drugs (’legal highs’) have become a global phenomenon which is developing at an 
unprecedented pace. The speed at which new drugs appear on the market — reflected not only in 
the sheer number of substances, but also in their diversity and in how they are produced, 
distributed and marketed — challenges established procedures for monitoring, responding to and 
controlling the use of new psychoactive substances. This in turn has generated a much higher 
level of political, general public (media, society at large) and scientific interest and concern about 
the ‘legal highs’ phenomenon.  
 
At political level, combating synthetic drugs and new psychoactive substances has been identified 
by the Committee on Internal Security (COSI) of the European Union as one of the EU priorities in 
combating organised crime and incorporated into a set of strategic goals and action plans for 
2012–13. This calls for a re-evaluation of both the information sources we use and the ways in 
which we disseminate information to inform policy, practice and the general public. The important 
work of the EMCDDA and Europol in this area informed the assessment of the Council Decision 
2005/387/JHA undertaken by the European Commission in the framework of the EU drugs action 
plan for 2009–12. The assessment concluded that the instrument is useful to tackle new 
substances at the EU level, in particular the Early-warning system. It also highlighted three major 
shortcomings related to the control phase: ‘it is not able to tackle the large increase in the number 
of new psychoactive substances on the market, because it addresses substances one by one, 
through a lengthy process; it is reactive, as substances submitted to control measures are quickly 
replaced with new ones with similar effects, often through small modifications of their chemical 
composition; it lacks options for control measures’. 
 
Currently, the Commission is carrying out an Impact assessment on a new instrument to replace 
the Council Decision 2005/387/JHA and, as announced in the Communication from the 
Commission ‘Towards a stronger European response to drugs’ (36), will propose stronger EU 
legislation on new psychoactive substances taking into account the rapid developments in this field 
and scientific evidence on the risks posed by these substances. The new proposal will: 
 
• ‘Enhance the monitoring and risk assessment of substances, by extending support for 
forensic analysis, toxicological, pharmacological and epidemiological studies. 
 
• Provide swifter and more sustainable answers to the emergence of these substances, 
possibly by exploring ways to address groups of substances, notwithstanding the need to 
determine scientifically the harmfulness to health of the individual substance. 
 
• Enable a faster response to the emergence of substances, including, possibly, through 
temporary bans on substances that pose immediate risks. 
 
• Better align laws in the field of drug control, product and food safety, consumer protection 
and medicines to cover the wide variety of substances that emerge.’ 
 
These developments have increased the profile of the EWS and the workload of the networks at 
national and European levels while resources often remain unchanged. As a response to the need 
to remain vigilant and react rapidly to the new substances and products identified, the EWS 
network has increased its operational capacity and has expanded to include not only new forensic 
science and toxicological laboratories but also a range of health and law-enforcement 
professionals, as well as many independent researchers. The current system, however, remains 
reactive rather than proactive. So whilst significant reporting capabilities now exist which facilitate 
the speedy exchange and triangulation of information from existing sources, the current system 
lacks the ability to anticipate emerging threats, by actively purchasing, synthesising and studying 
new compounds. Investment to improve capacity for investigative forensic analysis and research at 
the European level, linked to and coordinated by the EWS, is therefore essential. 
                                               
(36)  European Commission (2011), Communication from the Commission to the European Parliament and the Council, ‘Towards a 
stronger European response to drugs’, Brussels, 25.10.11, COM(2011) 689/2. 
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Annex 1.  New psychoactive substances reported to the EMCDDA and Europol for the 
  first time in 2011 under the terms of Council Decision 2005/387/JHA 
 
1. CRA-13 (naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone) – 11 January 2011 – 
Germany 
 
2. 4-MeO-PCP (4-methoxyphencyclidine) – 11 January 2011 – Finland 
 
3. Methylthienylpropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) – 13 January 2011 – 
Finland  
 
4. AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole)– 18 January 2011 – Latvia  
 
5. N,N-dimethylamphetamine (N,N-dimethyl-1-phenylpropan-2-amine) – 2 February 2011 – 
Bulgaria 
 
6. JWH-251 (2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)methanone) – 22 February 2011 – 
Germany  
 
7. JWH-018 adamantoyl derivative (1-adamantoyl(1-pentyl-1H-indol-3-yl)methanone) – 22 
February 2011 – Germany 
 
8. JWH-182 (1-pentyl-3-(4-ethyl-1-naphthoyl)indole) – 1 March 2011 – Denmark  
 
9. 5-IAI (5-iodo-2-aminoindane) – 1 March 2011 – United Kingdom  
 
10. JWH-250 derivative (1-(2-methylene-N-methylpiperidyl)-3-(2-methoxyphenylacetyl) indole) – 
17 March 2011 – Poland  
 
11. DMMA (3,4-dimethoxymethamphetamine) – 4 April 2011 – France  
 
12. α-PVP (α-pyrrolidinopentiophenone) – 4 April 2011 – France 
 
13. RCS-4 ortho isomer ((2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone) – 20 April 2011 – 
Sweden  
 
14. JWH-007 (1-pentyl-2-methyl-3-(1-naphthoyl)indole) – 25 May 2011 – Germany 
 
15. AM-1220 (1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(naphthyl)-methanone) – 25 May 
2011 – Germany 
 
16. AM-1220 azepane isomer (1-(1-methylazepan-3-yl)-1H-indol-3-yl](naphthyl)methanone) – 25 
May 2011 – Germany 
 
17. 5-HTP (5-hydroxytryptophan) – 25 May 2011 – Germany 
 
18. WIN 48,098 / pravadoline ((4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-
yl]methanone – 26 May 2011 – Germany and Poland 
 
19. 2C-C-NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine) – 
10 June 2011 – Finland  
 
20. Ostarine (3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-
propanamide) – 20 June 2011 – Sweden  
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21. JWH-122 fluoropentyl derivative (1-(5-fluoropentyl)-3-(4-methyl-naphthoyl)indole) – 20 June 
2011 – Netherlands and Germany 
 
22. 6-APB (6-(2-aminopropyl)benzofuran) – 30 June 2011 – Hungary 
 
23. 4-APB (4-(2-aminopropyl)benzofuran) – 30 June 2011 – Hungary 
 
24. RCS-4(C4) (4-methoxyphenyl-(1-butyl-1H-indol-3-yl)methanone) – 30 June 2011 – Hungary 
 
25. Phenazepam (7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) – 14 July 
2011 – Germany 
 
26. JWH-387 (1-pentyl-3-(4-bromo-1-naphthoyl)indole) – 20 July 2011 – Germany 
 
27. JWH-412 (1-pentyl-3-(4- fluoro-1-naphthoyl)indole) – 20 July 2011 – Germany 
 
28. JWH-307 ((5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone) – 5 August 2011 
– Finland 
 
29. AM-2233 (1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole) – 5 August 2011 – 
Finland 
 
30. Org27569 (5-Chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-
amide)) – 5 August 2011 – Finland 
 
31. Org 27759 (3-Ethyl-5-fluoro-1H-indole-2-carboxylic acid [2-94-dimethylamino-phenyl)-ethyl]-
amide) – 5 August 2011 – Finland 
 
32. Org 29647 (5-Chloro-3-ethyl-1H-indole-2-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide, 2-
enedioic acid salt) – 5 August 2011 – Finland 
 
33. N-ethylbuphedrone (2-(ethylamino)-1-phenylbutan-1-one) – 12 August 2011 – Denmark 
 
34. Brephedrone (1-(4-bromophenyl)-2-methylaminopropan-1-one) – 5 September 2011 – Finland  
 
35. Iso-pentedrone (1-methylamino-1-phenyl-pentan-2-one) – 30 September 2011 – Austria  
 
36. 4-Ethylmethcathinone ((RS)-2-methylamino-1-(4-ethylphenyl)propane-1-one) – 7 October 
2011 – Sweden  
 
37. 4-Benzylpiperidine ((phenylmethyl)piperidine) – 24 October 2011 – Bulgaria 
 
38. bk-MDDMA (1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one) – 28 October 2011 – 
Finland 
 
39. 4-methylbuphedrone (2-(methylamino)-1-(4-methylphenyl)butan-1-one) – 1 November 2011 – 
Netherlands 
 
40. Methoxyphenamine (1-(2-methoxyphenyl)-N-methylpropan-2-amine) – 30 November 2011 – 
United Kingdom 
 
41. Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate – 30 November 2011 – United 
Kingdom 
 
42. Camfetamine (N-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine – 30 November 2011 – United 
Kingdom 
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43. JWH-022 (naphthalen-1-yl(2-(pent-4-enyl)-1H-indol-3-yl)methanone – 30 November 2011 – 
United Kingdom 
 
44. Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-
a][1,4]diazepine) – 2 December 2011 – United Kingdom 
 
45. AM-2232 (5-[3-(1-naphthoyl)-1H-indol-1-yl]pentanenitrile) – 6 December 2011 – Germany 
 
46. 3-amino-1-phenyl-butane – 12 December 2011 – Belgium and Poland 
 
47. α-PBP (1-phenyl-2-pyrrolidino-butanone) – 20 December 2011 – Finland 
 
48. AM-694 chloro derivative (1-(5-chloropentyl)-3-(2-iodobenzoyl)indole) – 21 December 2011 – 
Germany 
 
49. 1-phenyl-1-propanamine – 21 December 2011 – Bulgaria  
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Annex 2.  Working definitions on new drugs as used by the EMCDDA  
 
The Joint Action 97/396/JHA and the Council Decision 2005/387/JHA provide legally binding 
definitions of the substances they cover; however, there are a number of other terms in common 
usage in this area which may cause confusion. For example, historically, new psychoactive 
substances have often been referred to as ‘designer drugs’ although today the term ‘legal highs’ is 
used more often. Much overlap exists between these terms but for practical purposes it is worth 
delineating the concepts. 
 
The term ‘new’ in all definitions is not intended to refer exclusively to newly invented/synthesised 
substances, but rather should be understood as ‘newly available’ or ‘newly misused’ substances.  
 
New synthetic drug (1997 Joint Action 97/396/JHA) 
 
 
The 1997 Joint Action 97/396/JHA (37) concerned new synthetic drugs ‘which are not currently 
listed in any of the Schedules to the 1971 United Nations Convention on Psychotropic Substances 
(38), and which pose a comparable serious threat to public health as the substances listed in 
Schedules I or II thereto and which have a limited therapeutic value’ (Article 2).  
 
 
The Joint Action ‘relates to end-products, as distinct from precursors in respect of which Council 
Regulation (EEC) No 3677/90 of 13 December 1990 laying down measures to be taken to 
discourage the diversion of certain substances to the illicit manufacture of narcotic drugs and 
psychotropic substances (39) and Council Directive 92/109/EEC of 14 December 1992 on the 
manufacture and the placing on the market of certain substances used in the illicit manufacture of 
narcotic drugs and psychotropic substances (40) provide for a Community regime’ (Article 2). 
 
New psychoactive substance (Council Decision 2005/387/JHA) 
 
Council Decision 2005/387/JHA broadened the scope of, and replaced, the 1997 Joint Action. Like 
the Joint Action, it takes the United Nations drug control Conventions as a point of reference, both 
to define the scope of the Decision (Article 2) and for the definition of a new psychoactive 
substance (Article 3).  
 
 
Council Decision 2005/387/JHA (41) defines a new psychoactive substance as ‘a new narcotic 
drug or a new psychotropic drug in pure form or in a preparation, that has not been scheduled 
under the 1961 United Nations Single Convention on Narcotic Drugs (42), and that may pose a 
threat to public health comparable to the substances listed in Schedule I, II or IV’ (new narcotic 
drug) or ‘under the 1971 United Nations Convention on Psychotropic Substances (38), and that may 
pose a threat to public health comparable to the substances listed in Schedule I, II, III or IV’ (new 
psychotropic drug). A preparation is defined as ‘a mixture containing a new psychoactive 
substance’ (Article 3). 
 
                                               
(37) Joint Action 97/396/JHA of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty on European Union, 
concerning the information exchange, risk assessment and the control of new synthetic drugs. Official Journal L 167, 
25/06/1997 p. 0001–0003. 
(38)  Convention on Psychotropic Substances, 1971, United Nations. 
(39) OJ No L 357, 20. 12. 1990, p. 1. Regulation as last amended by Commission Regulation (EEC) No 3769/92 (OJ No L 383, 29. 
12. 1992, p. 17).  
(40) OJ No L 370, 19. 12. 1992, p. 76. Directive as amended by Directive 93/46/EEC (OJ No L 159, 1. 7. 1993, p. 134).  
(41) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new 
psychoactive substances. Official Journal L 127, 20/05/2005 P. 0032–0037. 
(42)  Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic 
Drugs, 1961, United Nations. 
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This formulation has a number of implications, for example substances already listed under the UN 
Conventions are by definition excluded from the scope of the Council Decision. An important 
difference to the 1997 Joint Action is the inclusion of narcotic drugs (1961 UN Convention) and 
psychotropic substances which pose a comparable threat as substances listed in Schedules III or 
IV of the 1971 UN Convention. 
 
‘This Decision relates to end-products, as distinct from precursors in respect of which Council 
Regulation (EEC) No 3677/90 of 13 December 1990 laying down measures to be taken to 
discourage the diversion of certain substances to the illicit manufacture of narcotic drugs and 
psychotropic substances (43), and Regulation (EC) No 273/2004 of the European Parliament and of 
the Council of 11 February 2004 on drug precursors (44) provide for a Community regime’ (Article 
2). 
 
‘The new psychoactive substances covered by this Decision may include medicinal products as 
defined in Directive 2001/82/EC of the European Parliament and of the Council of 6 November 
2001 on the Community Code relating to veterinary medicinal products ( 45 ) and in Directive 
2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community 
Code relating to medicinal products for human use (46)’ (point 5 of the recital to the Council 
Decision). However, ‘substances of established and acknowledged medical value are therefore 
excluded from control measures based on this Decision’ (point 8 of the recital to the Council 
Decision) as are psychoactive substances used to manufacture a medicinal product (Article 7.3). 
 
Designer drugs and ‘legal highs’ 
 
It is not new to design a drug using the structure of a parent compound with known properties. The 
term ‘designer drugs’, however, emerged in the 1980s and became particularly popular with the 
emergence of the ‘ecstasy’ compounds (MDMA, MDA, MDE, etc) on the illicit drug market. 
 
Designer drugs were typically manufactured from chemical precursors in a clandestine laboratory. 
They can be best defined as unregulated (new) psychoactive substances intentionally designed to 
mimic the effects of controlled drugs by slightly altering their chemical structure in order to 
circumvent existing controls.  
 
‘Legal highs’ is an umbrella term for unregulated (new) psychoactive substances or products 
claiming to contain them that are specifically intended to mimic the effects of controlled drugs.  
 
The term encompasses a wide range of synthetic and/or plant-derived substances and products, 
which may be presented as ‘legal highs’ (emphasising ‘legality’), ‘research chemicals’ (implying 
legitimate research use), ‘party pills’ (alternative to ‘party drugs’), ‘herbal highs’ (stressing the plant 
origin), etc., which are usually sold via the Internet or in smart/head shops and in some cases 
intentionally mislabelled with purported ingredients differing from the actual composition. 
 
The ‘legal highs’ are usually manufactured in chemical laboratories outside of Europe and legally 
imported, either as chemicals or as already packaged products. The ‘legal highs’ market is 
distinguished by the speed at which suppliers circumvent drug controls by offering new alternatives 
to restricted products and advertising them with aggressive and sophisticated marketing strategies 
(room odorisers, herbal incenses, bath salts, plant fertilisers, collectors items, etc.). 
 
                                               
(43) OJ L 357, 20.12.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1232/2002 (OJ L 180, 
10.7.2002, p. 5). 
(44) OJ L 47, 18.2.2004, p. 1. 
(45) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).  
(46) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC (OJ L 136, 30.4.2004, p. 34).  
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The term ‘legal highs’ is used in inverted commas because describing these substances/products 
as ‘legal’ can be incorrect or misleading to customers as many of them can be covered, for 
example, by medicines or food safety laws. In addition, ‘legal highs’ products may contain 
substances controlled under drugs legislation. 
 
Finally, the term ‘legal highs’ is often used to refer to the phenomenon, rather than to a specific 
substance, similarly to the ‘Spice’ phenomenon, which is used to describe the marketing and sale 
of herbal products containing synthetic cannabinoid receptor agonists. 
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Annex 3.  Main groups of new psychoactive substances monitored by the EWS  
 
It is scientifically sound practice to classify the new psychoactive substances based on their 
chemical structure (i.e. in chemical families) (see table below). An exception is the group of 
synthetic cannabinoids, which can be placed in a category based on their mode of action rather 
than on their chemistry which varies considerably. Described below are the main families of 
psychoactive substances reported via the EWS so far (see also the EMCDDA drug profiles) (47). 
 
- Phenethylamines encompass a wide range of substances that may exhibit stimulant, 
entactogenic or hallucinogenic effects. Examples include the synthetic substances 
amphetamine, methamphetamine and MDMA (3,4-methylenedioxymethamphetamine) and 
mescaline, which occurs naturally. 
 
- Tryptamines include a number of substances that have predominantly hallucinogenic 
effects. The main representatives are the naturally occurring compounds 
dimethyltryptamine (DMT), psilocin and psilocybin (found in hallucinogenic mushrooms) as 
well as the semi-synthetic lysergic acid diethylamide (LSD). 
 
- Piperazines are represented by mCPP (1-(3-chlorophenyl) piperazine) and BZP (1-
benzylpiperazine), both of which are central nervous system stimulants. 
 
- Cathinones have stimulant effects. The main cathinone derivatives are the semi-synthetic 
methcathinone and the synthetic compounds mephedrone, methylone and MDPV (3,4-
methylenedioxypyrovalerone). 
 
- Synthetic cannabinoids are functionally similar to delta- 9-tetrahydrocannabinol (THC), the 
active principle of cannabis. Like THC, they can have hallucinogenic, sedative and 
depressant effects. They have been detected in herbal smoking mixtures such as ‘Spice’.  
 
- Other substances reported to the Early-warning system include various plant-derived and 
synthetic psychoactive substances (e.g. indanes, benzodifuranyls, narcotic analgesics, 
synthetic cocaine derivatives, ketamine and phencyclidine derivatives), which do not strictly 
belong to any of the previous families. Also included here are a small number of medicinal 
products and derivatives. 
                                               
(47) EMCDDA drug profiles, available at: http://www.emcdda.europa.eu/publications/drug-profiles  
 Family Parent compound Chemical structure of the parent compound Effects Representatives 
No of substances 
notified (2005–11) 
Phenethylamines phenethylamine (N) 
 
 
stimulant and/or 
hallucinogenic 
amphetamine, 
methamphetamine, 
MDMA, mescaline (N) 
26 
Tryptamines  tryptamine (N) 
N
H
NH2
 
hallucinogenic psilocin and psilocybin (N), 
dimethyltryptamine/DMT, 
lysergide/LSD (S) 
12 
Piperazines piperazine  
 
stimulant and/or 
hallucinogenic 
mCPP, BZP, TFMPP 8 
Cathinones cathinone (N) 
 
stimulant cathinone (N),  
mephedrone, methylone, 
methcathinone (S) 
 
34 
Synthetic 
cannabinoids 
N/A – the category includes a 
number of chemically 
unrelated but functionally 
similar families of cannabinoid 
receptor agonists that mimic 
the effects of ∆9 – THC 
(HU-210) 
 
hallucinogenic, 
sedative, 
depressant 
JWH-018,  
CP 47,497,  
HU-210 
44 
Miscellaneous 
substances 
N/A – the category includes 
new psychoactive plants as 
well as synthetic psychoactive 
substances, derivatives of 
well-established drugs not 
belonging to any of the 
families listed above, designer 
medicines, narcotic 
analgesics, etc. 
N/A stimulant, 
hallucinogenic, 
narcotic 
analgesic / 
opiate, 
depressant, etc. 
N/A 40 
 
  (N) naturally occurring, (S) semi-synthetic, (N/A) non applicable  
Appendix 
 
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment 
and control of new psychoactive substances 
 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32005D0387:EN:HTML 
